CagriSema
vs Survodutide.
Compare CagriSema and survodutide by amylin versus glucagon strategy, Phase 3 weight results, liver evidence, tolerability, and approval status.
Also searched as Survodutide vs CagriSema · GLP-1 glucagon vs GLP-1 amylin
What is the difference?
CagriSema and survodutide are different investigational once-weekly obesity drugs with no head-to-head trial. CagriSema combines cagrilintide and semaglutide to engage amylin and GLP-1 pathways and is under FDA review. Survodutide is a single glucagon and GLP-1 receptor dual agonist with Phase 3 obesity and liver-focused evidence. Both have reported Phase 3 weight results, but only CagriSema has a publicly documented US application under review at this evidence check. Neither is approved for marketing, and their separate trials cannot establish which program is better.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
CagriSema
Submitted to FDA - not yet approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 30 matched NCT records
- Sponsor
- Novo Nordisk
Survodutide
Investigational - not approved for marketing
- Route
- Once-weekly subcutaneous injection
- Registry
- 31 matched NCT records
- Sponsor
- Boehringer Ingelheim + Zealand Pharma
CagriSema vs Survodutide: how direct is the evidence?
No participant in the cited sources was randomized between CagriSema and Survodutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialSurvodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 5
- Results posted
- 0
- Recruiting site observations
- 155
matched NCT records
- Recruiting
- 3
- Results posted
- 3
- Recruiting site observations
- 774
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
- Featured trial anchors
- NCT05567796 · NCT05669755 · NCT07011667
Survodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
- Featured trial anchors
- NCT06066515 · NCT06066528 · NCT06077864 · NCT06309992
Compare the field, then read the limit.
The pair is strategically important because CagriSema emphasizes strong pivotal weight-management evidence and a near-term regulatory path, while survodutide adds a dedicated liver and body-composition research story. Those are different strengths, not proof that either program is the right choice for an individual. A useful comparison preserves receptor strategy, endpoint, estimand, population, discontinuation, and regulatory status.
| Field | CagriSema | Survodutide | How to interpret it |
|---|---|---|---|
| Mechanism | Amylin analogue plus GLP-1 receptor agonist combination | Glucagon plus GLP-1 receptor dual agonist | Both include GLP-1 activity, but amylin and glucagon strategies create different programs rather than interchangeable versions. |
| Weight evidence anchor | 22.7% at week 68 under the REDEFINE 1 trial-product estimand | Up to 16.6% at week 76 under the SYNCHRONIZE-1 efficacy estimand | Different estimands, trials, populations, and escalation plans prevent a direct or individual-level ranking. |
| Liver evidence | No dedicated liver outcome anchors the current profile | Phase 3 MRI liver-fat thresholds and a separate MASH program | A liver endpoint is clinically distinct from total weight change and should not be converted into an overall superiority claim. |
| Tolerability context | Gastrointestinal events were common in REDEFINE 1 | GI-event discontinuation was 19.0% versus 2.9% with placebo in SYNCHRONIZE-1 | Trial-specific definitions and exposure matter, so one disclosed rate does not establish a safer program across studies. |
| Current US status | New Drug Application submitted and under FDA review | Phase 3 program active and reporting, with no approval recorded | Regulatory maturity differs, but neither name currently establishes an approved product, pharmacy route, price, or supply. |
Why the headline numbers do not name a winner.
REDEFINE 1 reported 22.7% mean loss with CagriSema at week 68 under the trial-product estimand and 20.4% under the treatment-policy estimand. SYNCHRONIZE-1 reported up to 16.6% with survodutide at week 76 under an efficacy estimand and 13.0% under a treatment-regimen estimand. The trials did not share randomization, molecules, doses, escalation, populations, placebo responses, or missing-data rules. Survodutide's liver findings also answer a separate endpoint and do not create a weight-loss advantage claim.
Keep the comparison honest.
- 01
Compare weight estimands only as cross-trial orientation and keep each value attached to its duration, population, protocol, and placebo response.
- 02
Treat survodutide's liver results as liver-specific evidence rather than proof of better weight loss, safety, or suitability for every patient.
- 03
Keep CagriSema's FDA submission separate from approval and treat both development names as unable to authenticate an online product or seller.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →